Cancer Drug Combination Pricing: Genentech Offers Model For Tecentriq, Avastin
Executive Summary
Unique NDCs, Medicare reimbursement codes would allow for lower list prices for the drugs when used in combination for lung cancer, Genentech says.
You may also be interested in...
EU OK To Tecentriq-Avastin Combo In NSCLC Includes EGFR-Mutant, ALK-Positive Patients
EU approval of Tecentriq and Avastin together with chemo for the first-line treatment of metastatic non-squamous NSCLC is a positive advance for Roche, but analysts say the combo has a long way to go still to catch up with Merck & Co’s Keytruda combination.
Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval
The PD-L1 inhibitor's label excludes NSCLC patients with EGFR or ALK mutations, which could have been an advantage, but the indication largely reflects the registrational IMpower150 clinical trial's population.
Genentech, Amgen Face Big Impact From Part B International Pricing Index
Medicare spending on Genentech’s Rituxan and Lucentis, and Amgen’s Neulasta and Prolia/Xgeva, would have been $3.8bn less in 2016 using the proposed international pricing index model, CMS estimates.